Introduction {#s1}
============

Atrial fibrillation (AF) is a common cardiac arrhythmia, placing a significant burden on healthcare systems worldwide. It has been estimated that 33.5 million people suffering from AF with an increasing prevalence partly attributable to an aging population (Thacker et al., [@B35]; Chugh et al., [@B3]). Because pulmonary veins (PVs) are often the triggering sites for initiating and maintaining AF, circumferential PV isolation (CPVI) has been cornerstone of catheter ablation strategy to restore sinus rhythm for AF (Haïssaguerre et al., [@B9]; Jaïs et al., [@B13]; Kirchhof et al., [@B16]). Although feasibility and visibility of the three-dimensional electroanatomic mapping system have been improved, AF recurrence remains a problem due to PV reconnection after CPVI ablation (Ouyang et al., [@B29]). A study suggested that 20% of AF patients required repeat procedures after a median follow-up of 13 months (Hocini et al., [@B12]). Previous studies have suggested that PV re-connection can be identified by unmasking dormant conductions (DCs) induced by adenosine (Arentz et al., [@B1]; Theis et al., [@B36]; Ghanbari et al., [@B8]). The adenosine test has been used extensively to identify DCs (Arentz et al., [@B1]). The mechanism is thought to involve hyperpolarization of the membrane potential of dormant PVs by activating the I~KAdo~ inward rectifier current, which would transiently establish PV reconnection (Datino et al., [@B5]).

A recent systematic review and meta-analysis has demonstrated a positive outcome on assessment and ablation of dormant conduction (McLellan et al., [@B24]). However, some of the enrolled studies were based on segmental ablation strategy. Moreover, many studies suggested that whether DCs are associated with high rate of AF recurrence or adenosine test can improve clinical outcome of PVI remains controversial (Elayi et al., [@B6]; Kobori et al., [@B17]; Theis et al., [@B36]; Ghanbari et al., [@B8]; Kim et al., [@B15]). Several investigators have attempted to use the appearance of DCs as indication of further ablation using adenosine test after PVI for AF ablation, while results were restricted by low number of participants (McLellan et al., [@B24]). Therefore, if adenosine test will help to improve ablation success rates after CPVI remains controversial. We conducted this systematic review and meta-analysis to determine the clinical significance of unmasking DCs after CPVI based on long-term follow up using adenosine test as the guidance of extra ablation for AF patients.

Methods {#s2}
=======

Search Strategy
---------------

The databases Pubmed, EMBASE, Web of Science and Cochrane library were searched using searching terms and related items including keywords "dormant pulmonary vein conduction," "adenosine test," "circumferential pulmonary vein isolation," and "atrial fibrillation."

Inclusion and Exclusion Criteria
--------------------------------

The inclusion criteria were limited to articles published in English, involving human subjects of adult age, and published between 2010 and 2016. The exclusion criteria were: (1) ablation for non-AF patients; (2) no adenosine test used; (3) studies including fewer than 90 participants; (4) follow-up period \<12 months; (5) CPVI was not used for AF ablation; (6) articles that were case reports, reviews and meta-analyses.

Study Selection
---------------

Data from the different studies were entered in pre-specified spreadsheet in Microsoft Excel. All potentially relevant reports were retrieved as complete manuscripts and assessed for compliance with the inclusion criteria. Two reviewers (C.C. and D.L.) independently reviewed each included study and disagreements were resolved by adjudication with input from a third reviewer (Y.X.). Records matching searching goal were enrolled.

Data Analysis
-------------

The meta-analysis was performed using Review Manager (RevMan 5. 3, Cochrane Collaboration, Oxford, UK). Relative risk (RR) values with 95% confidence intervals (CI) were calculated. Categorical variables were pooled using the Mantel-Hanseal method. The I^2^ statistic from the standard chi-square test (χ^2^), which describes the percentage of the variability in effect estimates resulting from heterogeneity. A fixed effect model was used if I^2^ ≤ 0.25, otherwise the random effect model was used (Higgins and Green, [@B10]). *P*-value \< 0. 05 (two-tailed) was considered statistical significant.

Quality Assessment
------------------

We used the modified Newcastle-Ottawa scale for quality assessment of non-randomized trials and the methodological quality of RCTs was assessed by the components recommended by the Cochrane Collaboration (Higgins and Green, [@B10]). The quality of each trial except RCTs was quantified by a score of 0--9.

Results {#s3}
=======

Search Results and Study Characteristics
----------------------------------------

A flow diagram detailing the above search terms with inclusion and exclusion criteria is shown in Figure [1](#F1){ref-type="fig"}. A total of 4,669 records were identified from Pubmed, EMBASE, Web of Science and Cochrane Library databases. Of these, 17 studies met the inclusion criteria and were included in the final meta-analysis (Kumagai et al., [@B18]; Matsuo et al., [@B23]; Miyazaki et al., [@B26]; Van Belle et al., [@B38]; Cheung et al., [@B2]; Elayi et al., [@B6]; Kaitani et al., [@B14]; Zhang et al., [@B39]; Compier et al., [@B4]; Kobori et al., [@B17]; Kumar et al., [@B19]; Lin et al., [@B20]; Macle et al., [@B22]; Ghanbari et al., [@B8]; Kim et al., [@B15]; Tebbenjohanns et al., [@B34]). Twelve were prospective studies (Matsuo et al., [@B23]; Van Belle et al., [@B38]; Elayi et al., [@B6]; Kaitani et al., [@B14]; Compier et al., [@B4]; Kobori et al., [@B17]; Kumar et al., [@B19]; Lin et al., [@B20]; Macle et al., [@B22]; Theis et al., [@B36]; Ghanbari et al., [@B8]; Kim et al., [@B15]), four were retrospective studies (Kumagai et al., [@B18]; Matsuo et al., [@B23]; Miyazaki et al., [@B26]; Zhang et al., [@B39]) and four were randomized controlled trials (RCTs) (Kobori et al., [@B17]; Macle et al., [@B22]; Theis et al., [@B36]; Ghanbari et al., [@B8]). One study used prospective participants as a study group and retrospective cohort as control group (Tebbenjohanns et al., [@B34]). A total of 5,169 participants were included.

![Flow diagram of the study selection process.](fphys-09-01861-g0001){#F1}

These studies used selective venography or 3-dimensional Electroanatomical Mapping System (including CARTO, Ensite NavX) to identify the PV antrum and subsequently performed CPVI. In four studies, PVI was guided by cryoballoon (second generation cryoballoon, CB-2G) (Van Belle et al., [@B38]; Compier et al., [@B4]; Kumar et al., [@B19]; Tebbenjohanns et al., [@B34]). The endpoint of electrophysiological study was the presence of entrance block defined by the circular mapping catheter (Lasso, Biosense Webster) or the elimination of all PV potentials or establishment of a bidirectional conduction block between left atrium (LA) and PVs. All participants underwent further ablation if DCs was induced. Two studies described the additional use of superior vena cava isolation (Compier et al., [@B4]; Kumar et al., [@B19]).

In this meta-analysis, we supposed to determine: (1) if adenosine test would help to increase the success rate of PVI; and (2) furthermore, if DCs induced by adenosine play an important role in AF recurrence after CPVI. Hence, in the first part, Group A (+) and Group A (−) were divided according to whether adenosine was administrated or not. And in the second part, Group DC (+) and Group DC (−) were divided according to whether the DCs appeared or not after adenosine administration. All of DCs induced by adenosine test in Group A (+) and Group DC (+) patients were eliminated after CPVI. The baseline characteristics of these studies are listed in Table [1](#T1){ref-type="table"}, and those of procedure parameter are shown in Table [2](#T3){ref-type="table"}. Quality assessment of the included studies was made using the Newcastle--Ottawa Scale for non-randomized case--control studies and the Cochrane Collaboration\'s tool for randomized trials (Table [3](#T5){ref-type="table"}).

###### 

Basic information and operation details in Group A (+) and Group A (−).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Article**                    **Comparator**\       **Publish**\   **Center**   **Study**\                                         **Electroanatomic**\                     **Type of AF**\                                                                                        **Ablation**\                                                                                           **RF**\                                                                         **MPT**\                                     **MFT**\
                                 **groups**            **year**                    **type**                                           **mapping system**                       **ablation[^\*^](#TN1){ref-type="table-fn"}**                                                          **endpoint**                                                                                            **energy[^\*^](#TN1){ref-type="table-fn"}**                                     **(min)[^\*^](#TN1){ref-type="table-fn"}**   **(min)[^\*^](#TN1){ref-type="table-fn"}**
  ------------------------------ --------------------- -------------- ------------ -------------------------------------------------- ---------------------------------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- -------------------------------------------- --------------------------------------------
  Kobori et al., [@B17]          ATP guided PVI\       2015           Multiple     Prospective RCT[^\*^](#TN1){ref-type="table-fn"}   CARTO, Ensite NavX                       CPVI[^\*^](#TN1){ref-type="table-fn"}                                                                  Disappearance of DC in ATP-guided PVI group[^\*^](#TN1){ref-type="table-fn"}                            35 W[^\*^](#TN1){ref-type="table-fn"} (limited to 20 W on the posterior wall)   195\                                         58.4\
                                 Conventional PVI                                                                                                                                                                                                                                                                                                                                                                                                                             192                                          58.0

  Theis et al., [@B36]           Adenosine group\      2015           Single       Prospective RCT                                    Ensite NavX                              Standardized PVI procedure[^\*^](#TN1){ref-type="table-fn"}                                            Elimination of PV potentials recorded on circumferential PV catheter[^\*^](#TN1){ref-type="table-fn"}   Maximum power 30 W                                                              126 ± 45                                     23 ± 9
                                 Control group                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Elayi et al., [@B6]            Group 1 Group 1A\     2013           Single       Prospective CT[^\*^](#TN1){ref-type="table-fn"}    Lasso, Lasso 2515, Biosense-Webster      PVAI, SVC was also isolated by ablation of the sharp SVC potentials[^\*^](#TN1){ref-type="table-fn"}   Electrical isolation of the\                                                                            30--35 W on the posterior wall; 40--45 W at other locations                     --                                           60 ± 24\
                                 Group 1B\                                                                                                                                                                                                                                            PV antrum region[^\*^](#TN1){ref-type="table-fn"}                                                                                                                                                                                    53 ± 17
                                 Group 1C\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                 Control Group 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Ghanbari et al., [@B8]         Adenosine\            2016           Single       Prospective RCT                                    CARTO, Biosense-Webster                  Encircle PV ostia                                                                                      --                                                                                                      25 W                                                                            216.8 ± 60.6\                                33.6 ± 13.4\
                                 No adenosine                                                                                                                                                                                                                                                                                                                                                                                                                                 202.0 ± 62.5                                 32.1 ± 13.2

  Kumagai et al., [@B18]         ATP group\            2010           Single       Retrospective analysis                             BeeAT, Japan Lifeline Co., Ltd., Japan   Circumferential ablation                                                                               Creation of bidirectional conduction block                                                              ≤35 W and ≤30 W on sites near the esophagus                                     --                                           --
                                 Control group                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Compier et al., [@B4]          Adenosine + group\    2015           Single       Prospective CT                                     Lasso 2515 catheter                      PVI guided by cryoballoon and circular mapping catheter                                                Entrance and exit was block                                                                             --                                                                              57 + 21\                                     24 + 11\
                                 Adenosine -- group                                                                                                                                                                                                                                                                                                                                                                                                                           51 + 11                                      34 + 10

  Kumar et al., [@B19]           Adenosine group\      2015           Single       Prospective CT                                     --                                       Inner lumen endoluminal spiral catheter, CB-2G balloon guided PVI[^\*^](#TN1){ref-type="table-fn"}     Twice 4 min applications of each PV and there was entrance and exit block after adenosine test          --                                                                              174 + 44\                                    34 + 13\
                                 Non-adenosine group                                                                                                                                                                                                                                                                                                                                                                                                                          212 + 47                                     40 + 18

  Van Belle et al., [@B38]       Adenosine group\      2012           Single       Prospective CT                                     A circular mapping catheter              28 mm, 12 Fr cryoballoon catheter                                                                      --                                                                                                      --                                                                              202 ± 68                                     41 ± 24
                                 No adenosine group                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Tebbenjohanns et al., [@B34]   Study group\          2016           Single       Prospective retrospective                          A spiral mapping catheter                CB[^\*^](#TN1){ref-type="table-fn"} catheter                                                           --                                                                                                      --                                                                              78 + 12\                                     14 + 3\
                                 Control group                                                                                                                                                                                                                                                                                                                                                                                                                                93 + 12                                      14 + 4
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Article**                    **Comparator groups**   **ATP (dose/period time)**                                                                                                                                   **Follow up(m)**   **Follow up(method)**                                                                                               **Free form AF** ***n*** **(%)**   **P**                                                                                                          **Conclusion[^\*^](#TN1){ref-type="table-fn"}**
  ------------------------------ ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------ ------------------------------------------------------------------------------------------------------------------- ---------------------------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------------
  Kobori et al., [@B17]          ATP guided PVI\         0.4 mg/kg without waiting period                                                                                                                             15                 12-lead electrocardiogram, one-channel electrocardiogram, ambulatory electrogram recorder, 24 h Holter monitoring   79.2%\                             Primary endpoint 0.09 secondary efficacy endpoint 0.07                                                         --
                                 Conventional PVI                                                                                                                                                                                                                                                                                                            76.9%                                                                                                                                             

  Theis et al., [@B36]           Adenosine group\        ≥10-mg adenosine, incremental values increased by 5-mg steps                                                                                                 24.8 ± 4.01\       48-h Holter-ECGs, ECG[^\*^](#TN1){ref-type="table-fn"}                                                              88%\                               0.001 (overall follow-up)                                                                                      \+
                                 Control group                                                                                                                                                                        29.16 ± 4.87                                                                                                                           92%                                                                                                                                               

  Elayi et al., [@B6]            Group 1 Group 1A\       Intravenous injection of 12 mg. ISP infusion was started: 5 mcg for 3 min, then 10 mcg for 3 min, 15 mcg for 3 min, 20 mcg for 3 min, and 30 mcg for 3 min   22 ± 8             48-h Holter monitors, event recorder                                                                                --                                 Groups 1A/1B and 1B/1C (*P* \< 0.001) groups 1A and group 1C (*P* = 1.0) groups 1 and groups 2 (*P* = 0.038)   \+
                                 Group 1B\                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                 Group 1C\                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                 Control Group 2                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Ghanbari et al., [@B8]         Adenosine\              6--24 mg adenosine ISP infused at rates of 5, 10, 15, and 20 μg/min for 2 min at each infusion rate in each group as above                                   9.2 ± 7            Auto-triggered event recorder                                                                                       24/61 \[39.3%\]\                   0.83                                                                                                           --
                                 No adenosine                                                                                                                                                                                                                                                                                                                23/68 \[33.8%\]                                                                                                                                   

  Kumagai et al., [@B18]         ATP group\              10 mg ATP administered during an intravenous ISP infusion (5 μg/ min)[^\*^](#TN1){ref-type="table-fn"}                                                       16 ± 5.2\          ECG, 24-h Holter monitoring                                                                                         76.4%\                             0.03                                                                                                           \+
                                 Control group                                                                                                                                                                        16 ± 6.9                                                                                                                               62.3%                                                                                                                                             

  Compier et al., [@B4]          Adenosine + group\      Adenosine initiated at 6/12 mg, increased up to 30 mg until at least one atrial beat with AV-block was observed with 30-min waiting period                   12 + 1\            ECG, 24 h Holter                                                                                                    64%\                               0.02                                                                                                           \+
                                 Adenosine -- group                                                                                                                                                                   11 + 1                                                                                                                                 47%                                                                                                                                               

  Kumar et al., [@B19]           Adenosine group\        Waiting time of 30 min, 12--15 mg adenosine                                                                                                                  13 + 1\            --                                                                                                                  84%\                               0.06                                                                                                           --
                                 Non-adenosine group                                                                                                                                                                  12 + 2                                                                                                                                 79%                                                                                                                                               

  Van Belle et al., [@B38]       Adenosine group\        25 mg adenosine                                                                                                                                              17 ± 5             ECG, 24-h Holter recording,\                                                                                        23 (68%)\                          0.04                                                                                                           \+
                                 No adenosine group                                                                                                                                                                                      a symptom questionnaire, Transtelephonic Holter monitoring                                                          29 (46%)                                                                                                                                          

  Tebbenjohanns et al., [@B34]   Study group\            A bolus of adenosine with a short duration                                                                                                                   15 ± 3.6           24-h Holter monitoring\                                                                                             81%\                               NS                                                                                                             --
                                 Control group                                                                                                                                                                                           and external event recording                                                                                        79%                                                                                                                                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Parts of values represent mean ± difference. Conclusion^\*^:(+) represents experimental group and controlled group have significant difference;(−) represents experiment group and controlled group have no significant difference. PVI^\*^, pulmonary vein isolation; CPVI^\*^, circumferential pulmonary vein isolation; PV^\*^, pulmonary vein; RCT^\*^, randomized controlled trial; DC^\*^, dormant conduction; CT^\*^, clinical trial; ISP^\*^, isoproterenol; MPT^\*^, mean procedure time; MFT^\*^, mean fluoroscopic time; AF^\*^, atrial fibrillation; RF^\*^, radiofrequency; SVC^\*^, superior vena cava; ECG^\*^, electrocardiograph; CB-2G^\*^, second-generation cryoballoon; CB, cryoballoon; W^\*^, watt*.

###### 

Baseline information in Group A (+) and Group A (−).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Article**                    **Comparator\         **Numbers of Sample**   **Numbers of group**   **Age**        **Male *n* (%)**   **PSAF[^\*^](#TN2){ref-type="table-fn"}*n* (%)**   **AF history**          **LAD[^\*^](#TN2){ref-type="table-fn"} (mm)**   **HP[^\*^](#TN2){ref-type="table-fn"} (*n*/%)**
                                 groups**                                                                                                                                                                                                                          
  ------------------------------ --------------------- ----------------------- ---------------------- -------------- ------------------ -------------------------------------------------- ----------------------- ----------------------------------------------- -------------------------------------------------
  Kobori et al., [@B17]          ATP guided PVI\       2120                    1112\                  58.6+8.6\      856 (77.0)\        737 (66.3)\                                        23.3 \[8.8--60.8\] m\   38.9 + 6.3\                                     535 (47.6%)\
                                 Conventional PVI                              1001                   68.5+8.8       723 (72.7)         683 (68.2)                                         26.4 \[9.4--67.5\] m    39.2 + 6.2                                      590 (58.9%)

  Theis et al., [@B36]           Adenosine group\      152                     76\                    63 ± 10\       45 (59)\           152 (100%)                                         --                      22.17 ± 5.18 cm^2^\                             46 (61)\
                                 Control group                                 76                     64 ± 9.11      33 (43)                                                                                       23.24 ± 4.81 cm^2^                              53 (70)

  Elayi et al., [@B6]            Group 1\              388                     32\                    63.5 ± 10.5\   20 (62%)\          3 (10%)\                                           4.7 ± 3.7 y\            46.3 ± 4.3\                                     15 (47%)\
                                 Group 1A\                                     83\                    63.6 ± 10.1\   54 (65%)\          11 (13%)\                                          4.6 ± 4 y\              46.0 ± 4.2\                                     39 (47%)\
                                 Group 1B\                                     74\                    63.9 ± 10.4\   58 (78%)\          12 (16%)\                                          4.4 ± 3.8 y\            45.8 ± 4.2\                                     32 (43%)\
                                 Group 1C\                                     \                      \              \                  \                                                  \                       \                                               \
                                 Control Group 2                               196                    63.6 ± 10.2    150 (76%)          30 (15%)                                           4.7 ± 4.1 y             46.3 ± 4.3                                      93 (48%)

  Ghanbari et al., [@B8]         Adenosine\            129                     61\                    59.7 ± 8.7\    37 (60.6%)\        129 (100%)                                         --                      41.0 ± 5.3\                                     33 (54.1%)\
                                 No adenosine                                  68                     58.9 ± 10.7    53 (77.9%)                                                                                    41.2 ± 6.4                                      28 (45.9%)

  Kumagai et al., [@B18]         ATP group\            212                     106\                   58 ± 11\       70.0%\             94 86                                              4.5 ± 3.9 y\            39.4 ± 5.4\                                     21.7\
                                 Control group                                 106                    59 ± 10        78.3%                                                                 5.0 ± 5.5 y             39.7 ± 5.7                                      20.0

  Compier et al., [@B4]          Adenosine + group\    98                      36\                    61 + 10\       78%\               86%\                                               64 + 60 m\              42 + 6.7\                                       50\
                                 Adenosine -- group                            62                     59 + 11        70%                90%                                                58 + 53 m               42 + 5.6                                        52

  Kumar et al., [@B19]           Adenosine group\      90                      45\                    57.4 + 9.5\    27\                40\                                                8 + 7.1 y\              LA volume: 72 + 14 cc\                          14 (31%)\
                                 Non-adenosine group                           45                     56.6 + 11.2    34                 39                                                 7 + 3.8 y               77 + 18 cc                                      18 (40%)

  Van Belle et al., [@B38]       Adenosine group\      99                      34\                    57 ± 12\       24\                34\                                                7 ± 5 y\                45 ± 7\                                         --
                                 No adenosine group                            65                     57 ± 12        46                 65                                                 7 ± 6 y                 42 ± 6                                          

  Tebbenjohanns et al., [@B34]   Study group\          192                     53\                    66 + 10\       27\                38 (72%)\                                          6 + 4 y\                40 + 6\                                         --
                                 Control group                                 139                    61 + 11        75                 87 (63%)                                           5 + 3 y                 41 + 7                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Article**                    **Comparator groups**   **Ischemic heart disease**   **Diabetes (n/%)**   **LVEF[^\*^](#TN2){ref-type="table-fn"}** **(%)**
  ------------------------------ ----------------------- ---------------------------- -------------------- ---------------------------------------------------
  Kobori et al., [@B17]          ATP guided PVI\         17 (1.5%)\                   141 (12.7%)\         64.2 + 7.9\
                                 Conventional PVI        20 (2.0%)                    141 (14.1%)          64.6 + 7.3

  Theis et al., [@B36]           Adenosine group\        --                           --                   54.74 ± 1.61\
                                 Control group                                                             55

  Elayi et al., [@B6]            Group 1\                5 (15%)\                     4 (12%)\             54 ± 12\
                                 Group 1A\               13 (16%)\                    8 (10%)\             55 ± 9\
                                 Group 1B\               15 (20%)\                    11 (15%)\            57 ± 11\
                                 Group 1C\               40 (20%)                     25 (13%)             55 ± 9
                                 Control Group 2                                                           

  Ghanbari et al., [@B8]         Adenosine\              --                           6 (9.8%)\            59.7 ± 5.4\
                                 No adenosine                                         8 (11.8%)            59.3 ± 5.6

  Kumagai et al., [@B18]         ATP group\              --                           --                   65.1 ± 8.9\
                                 Control group                                                             63.8 ± 9.6

  Compier et al., [@B4]          Adenosine + group\      --                           --                   --
                                 Adenosine -- group                                                        

  Kumar et al., [@B19]           Adenosine group\        9 (20%)\                     --                   56 + 6\
                                 Non-adenosine group     8 (18%)                                           57 + 8

  Van Belle et al., [@B38]       Adenosine group\        --                           --                   --
                                 No adenosine group                                                        

  Tebbenjohanns et al., [@B34]   Study group\            --                           --                   --
                                 Control group                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

*Abbreviations as per Table [1A](#T1){ref-type="table"}. PSAF^\*^, paroxysmal atrial fibrillation; LAD, left atrial diameter; HP, hypertension; LVEF, left ventricular ejection fraction*.

###### 

Basic information and operation details in Group DC (+) and Group DC (−).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Article**               **Comparator groups**                                                  **Publish year**   **Center**   **Study type**                    **Electroanatomic mapping system**   **Type of AF ablation**                                               **Ablation end point**                                                                                                                                                           **RF energy**                         **MPT (min)**   **MFT (min)**
  ------------------------- ---------------------------------------------------------------------- ------------------ ------------ --------------------------------- ------------------------------------ --------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------- --------------- ---------------
  Zhang et al., [@B39]      ATP (+) Group\                                                         2014               Single       Retrospective analysis            CARTO                                Standard CPVI procedure by irrigated\                                 Entrance block                                                                                                                                                                   --                                    --              --
                            ATP (−) Group                                                                                                                                                                 tip catheter                                                                                                                                                                                                                                                                                                 

  Kim et al., [@B15]        Dormant conduction\                                                    2016               Single       Prospective CT                    CARTO                                4-mm open irrigated catheter, CPVI                                    No PV potentials recorded by the circular mapping catheter. Exit block was confirmed when PV to LA dissociation was observed during PV pacing[^\*^](#TN3){ref-type="table-fn"}   25--35 W                              194.0 ± 55.4    67.9 ± 51.9
                            No dormant conduction                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Kaitani et al., [@B14]    DC -- group\                                                           2014               Multiple     Prospective observational study   CARTO XP, NavX                       CPVI by irrigated-tip catheters                                       Entrance block as shown by t elimination of the superior and inferior pulmonary vein potentials                                                                                  20--40 W                              --              --
                            DC+ group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Macle et al., [@B22]      Adenosine + No further ablation\                                       2015               Multiple     Prospective RCT                   --                                   Circumferential ablation at the PV ostia by the circular catheter     PV spikes are no longer recorded                                                                                                                                                 --                                    --              --
                            Adenosine + Ablation until adenosine -- Adenosine -- Registry group\                                                                                                                                                                                                                                                                                                                                                                                                                       
                            Adenosine -- routine follow-up                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Matsuo et al., [@B23]     Group A: dormant PV conduction \[+\]\                                  2010               Single       Retrospective analysis            CARTO                                Circular catheter venography was performed                            Establishment of a bidirectional conduction block between LA and PV                                                                                                              25--35 W                              220 ± 71\       125 ± 43\
                            Group B: dormant PV conduction \[--\]                                                                                                                                                                                                                                                                                                                                                                                                                                      217 ± 65        132 ± 54

  Miyazaki et al., [@B26]   Group-1:no adenosine response\                                         2012               Single       Retrospective analysis            CARTO                                Circumferentially extensively ablated by circular mapping catheters   The elimination of all PV potentials                                                                                                                                             35 W                                  --              --
                            Group-2: adenosine response                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Cheung et al., [@B2]      Dormant conduction \[+\] group\                                        2013               Single       Prospective CT                    CARTO or EnsiteNavX                  Circumferential ablation                                              \(1\) Entrance block or abolition of PV\                                                                                                                                         45 W (\<30 W on the posterior wall)   --              --
                            Dormant conduction \[-\] group                                                                                                                                                                                                                      Potentials\                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                (2) Exit block with absence of left atrial capture\                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                of the circular mapping catheter                                                                                                                                                                                                       

  Lin et al., [@B20]        Dormant conduction group\                                              2015               Single       Prospective CT                    CARTO or EnsiteNavX                  Circumferential ablation                                              \(1\) Entrance block\                                                                                                                                                            15--50 W                              --              --
                            No Dormant conduction group                                                                                                                                                                                                                         or abolition of PV\                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                potentials\                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                (2) Exit\                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                block with absence of left atrial capture of the circular mapping catheter                                                                                                                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Article**               **Comparator groups**                                                  **ATP (dose/period time)**                                                                                                                                           **Follow up (m)**   **Follow up (method)**                                                              **Free form AF** ***n*** **(%)**   ***P***                  **Conclusion**
  ------------------------- ---------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- ----------------------------------------------------------------------------------- ---------------------------------- ------------------------ ----------------
  Zhang et al., [@B39]      ATP (+) Group\                                                         ATP 40 mg during an intravenous ISP infusion (5 μg/min)                                                                                                              18.7 ± 6.4          --                                                                                  30/39 (76.9%)\                     ATP (+-) vs. ATP (++)\   \+
                            ATP (−) Group                                                                                                                                                                                                                                                                                                                                       176/261 (67.3%)                    *p* = 0.02               

  Kim et al., [@B15]        Dormant conduction\                                                    20 mg If dormant conduction was observed, 12 and 6 mg adenosine were injected serially and dormant conduction was observed to identify the adequate adenosine dose   12                  24-h Holter monitoring                                                              74.8%\                             0.9                      --
                            No dormant conduction                                                                                                                                                                                                                                                                                                                               72.6%                                                       

  Kaitani et al., [@B14]    DC -- group\                                                           A continuous isoproterenol infusion (0.5--2 mg/min) at begin. A waiting period of at least 15 min,40 mg ATP                                                          27.1 ± 15           ECG, Holter, an event recorder                                                      66.7%\                             0.12                     --
                            DC+ group                                                                                                                                                                                                                                                                                                                                           80.0%                                                       

  Macle et al., [@B22]      Adenosine + No further ablation\                                       12 mg ATP 20 min observation period                                                                                                                                  12.3                Holter                                                                              51 (37.2%)\                        ①vs. 0.0002②\            \+
                            Adenosine + Ablation until adenosine -- Adenosine -- Registry group\                                                                                                                                                                                                                                                                                88 (59.9%)\                        ①vs. 0.0421③\            
                            Adenosine -- routine follow-up                                                                                                                                                                                                                                                                                                                      56 (48.7%)\                        ②vs. 0.0639③             
                                                                                                                                                                                                                                                                                                                                                                                ---                                                         

  Matsuo et al., [@B23]     Group A: dormant PV conduction \[+\]\                                  20 mg of ATP under ISPl infusions                                                                                                                                    30 ± 13             Electrocardiogram recordings 24-h ambulatory monitoring                             125 (89.9%)\                       0.79                     --
                            Group B: dormant PV conduction \[--\]                                                                                                                                                                                                                                                                                                               86 (91.5%)                                                  

  Miyazaki et al., [@B26]   Group-1: no adenosine response\                                        40 mg during intravenous ISP infusion                                                                                                                                12                  ECG, Holter, event recorder                                                         72.8%\                             0.03                     \+
                            Group-2: adenosine response                                                                                                                                                                                                                                                                                                                         51.3%                                                       

  Cheung et al., [@B2]      Dormant conduction \[+\] group\                                        12-mg adenosine was injected followed by 20 mL saline.                                                                                                               12.5                7--14 days continuous mobile telemetry\                                             64%\                               0.062                    --
                            Dormant conduction \[--\] group                                                                                                                                                                                                                                 monitors                                                                            76%                                                         

  Lin et al., [@B20]        Dormant conduction group\                                              A-12 mg adenosine was injected followed by 20 cc of saline with\                                                                                                     20 ± 9              7--14 days continuous mobile telemetry monitors; telephone follow-up for symptoms   47%\                               0.12                     --
                            No Dormant conduction group                                            escalating doses of 18 mg and 24 mg if atrioventricular block was not observed.                                                                                                                                                                                              61%                                                         
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Abbreviations as per Table [1A](#T1){ref-type="table"}. LA^\*^, left atrial*.

###### 

Baseline information in Group DC (+) and Group DC (−).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Article**               **Comparator groups**                                                  **Numbers\    **Numbers of group**   **Age**        **Male *n* (%)**   **PSAF *n* (%)**   **AF history**   **LAD (mm)**   **HP (%)**    **Ischemic heart disease**   **Diabetes**   **LVEF (%)**
                                                                                                   of sample**                                                                                                                                                                         
  ------------------------- ---------------------------------------------------------------------- ------------- ---------------------- -------------- ------------------ ------------------ ---------------- -------------- ------------- ---------------------------- -------------- --------------
  Zhang et al., [@B39]      ATP (+) Group\                                                         300           39\                    52.7 ± 4.9\    19\                300 (100%)\        3.2 ± 0.6 y\     37.4 ± 3.4\    --            --                           --             61.4 ± 2.7\
                            ATP (−) Group                                                                        261                    54.4 ± 6.7     125                --                 3.7 ± 0.4 y      36.8 ± 4.2                                                               62.2 ± 3.6

  Kim et al., [@B15]        Dormant conduction\                                                    378           92\                    60.7 ± 11.3\   69\                49 (53.3%)\        --               43.7 ± 12.6\   44 (47.8%)\   --                           17 (18.5%)\    --
                            No dormant conduction                                                                286                    60.2 ± 11.1    186                151 (52.8%)                         43.1 ± 13.5    146 (51.0%)                                43 (15.0%)     

  Kaitani et al., [@B14]    DC -- group\                                                           110           75\                    62.5 + 9.8\    55\                --                 45.9 ± 40 m\     38.2 + 6\      49 (65.3%)\   --                           8 (10.7%)\     --
                            DC+ group                                                                            35                     61.8 + 9.2     26                                    59.3 ± 7 m       38.7 + 0.5     22 (62.9%)                                 4 (11.4%)      

  Macle et al., [@B22]      Adenosine + No further ablation\                                       550           137\                   58.4\          97\                100%               3.4 y\           39.6\          50 (36.5%)\   15 (10.9%)\                  6 (4.4%)\      60.1\
                            Adenosine + Ablation until adenosine -- Adenosine -- Registry group\                 147\                   60.2\          108\                                  4.0 y\           40.1\          62 (42.2%)\   16 (10.9%)\                  8 (5.4%)\      59.9\
                            Adenosine -- routine follow-up                                                       117\                   58.9\          87\                                   3.0 y\           40.1\          54 (46.2%)\   10 (8.5%)\                   11(9.4%)\      59.1\
                                                                                                                 133                    60.4           86                                    4.0 y            39.9           54 (40.6%)    14 (10.5%)                   8 (6.0%)       60.2

  Matsuo et al., [@B23]     Group A: dormant PV conduction \[+\]\                                  233           139\                   54.3 ± 9.6\    122\               89\                4.5 ± 4.0 y\     38.5 ± 5.5\    31 (22.3%)\   --                           --             65.9 ± 6.6\
                            Group B: dormant PV conduction \[--\]                                                94                     54.2 ± 10.9    84                 55                 4.3 ± 3.7 y      39.7 ± 5.7     27 (28.7%)                                                65.8 ± 7.4

  Miyazaki et al., [@B26]   Group-1: no adenosine response\                                        109           70\                    61.4 ± 11.2\   58\                109 (100%)         60.7 ± 59.1 m\   38.1 ± 5.4\    24 (34%)\     --                           --             65.8 ± 8.3\
                            Group-2: adenosine response                                                          39                     59.4 ± 10.3    33                                    57.4 ± 43.9 m    39.4 ± 5.5     16 (41%)                                                  66.4 ± 9.0

  Cheung et al., [@B2]      Dormant conduction \[+\] group\                                        152           44\                    62 ± 9\        34\                29 (66%)\          29 (66)\         4.0 ± 0.6\     23 (52%)\     --                           7 (16%)\       60 ± 11\
                            Dormant conduction \[--\] group                                                      108                    60 ± 11        86                 67 (62%)           67 (62)          4.3 ± 0.7      42 (39%)                                   11 (10%)       59 ± 11

  Lin et al., [@B20]        Dormant conduction group\                                              152           45\                    61 ± 9\        35\                30 (67%)\          30 (67)\         --             23 (51%)\     --                           7 (16%)\       60 ± 10\
                            No Dormant conduction group                                                          107                    59 ± 11        85                 66 (62%)           66 (62)                         41 (38%)                                   11 (10%)       59 ± 11
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Abbreviations as per Table [1A](#T1){ref-type="table"}*.

###### 

Assessment of the quality of included studies in Group A (+) and Group A (−)[^\*^](#TN5){ref-type="table-fn"}.

  **Study**                      **Assessment**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   **Classification (attributable stars)**
  ------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------
  Kobori et al., [@B17]          Unclear risk of selection bias (insufficient information about the sequence generation and allocation concealment); Unclear risk of performance bias (insufficient information about blinding of participants and personnel); Unclear risk of detection bias (insufficient information about blinding of outcome assessment); low risk of attrition bias (complete outcome for all the patients enrolled); Unclear risk of reporting bias (insufficient information about selective reporting); Unclear risk of other bias (insufficient information about other sources of bias).                                                                                                                                                               --
  Theis et al., [@B36]           Unclear risk of selection bias (insufficient information about the sequence generation and allocation concealment); Unclear risk of performance bias (insufficient information about blinding of participants and personnel); Unclear risk of detection bias (insufficient information about blinding of outcome assessment); low risk of attrition bias (complete outcome for all the patients enrolled); Unclear risk of reporting bias (insufficient information about selective reporting); Unclear risk of other bias (insufficient information about other sources of bias).                                                                                                                                                               --
  Elayi et al., [@B6]            Adequate case definition; consecutive series of cases; hospital controls; adequate information concerning the selection and definition of controls; groups controlled for all the baseline characteristics; ascertainment of outpatient exposure to adenosine text based on medical records for experiment groups; patients not blinded to case--control status.; same non-Response rate for both groups.                                                                                                                                                                                                                                                                                                                                        6
  Ghanbari et al., [@B8]         Low risk of selection bias (treatment assignment was concealed in numbered, sealed envelopes, the research staff opened the envelope and revealed the randomization assignment in the electrophysiology laboratory and insufficient information about the sequence generation); Unclear risk of performance bias (insufficient information about blinding of participants and personnel); Unclear risk of detection bias (insufficient information about blinding of outcome assessment); low risk of attrition bias (complete outcome for all the patients enrolled); Unclear risk of reporting bias (insufficient information about selective reporting); Unclear risk of other bias (insufficient information about other sources of bias).   --
  Kumagai et al., [@B18]         Adequate case definition; consecutive series of cases; hospital controls; adequate information concerning the selection and definition of controls; groups controlled for all the baseline characteristics; ascertainment of outpatient exposure to adenosine text based on medical records for experiment groups; patients not blinded to case--control status.; same non-Response rate for both groups.                                                                                                                                                                                                                                                                                                                                        6
  Compier et al., [@B4]          Adequate case definition; consecutive series of cases; hospital controls; adequate information concerning the selection and definition of controls; groups controlled for all the baseline characteristics; ascertainment of outpatient exposure to adenosine text based on medical records for experiment groups; patients not blinded to case--control status.; same non-Response rate for both groups.                                                                                                                                                                                                                                                                                                                                        6
  Kumar et al., [@B19]           Adequate case definition; consecutive series of cases; hospital controls; adequate information concerning the selection and definition of controls; groups controlled for all the baseline characteristics; ascertainment of outpatient exposure to adenosine text based on medical records for experiment groups; patients not blinded to case--control status.; same non-Response rate for both groups.                                                                                                                                                                                                                                                                                                                                        6
  Van Belle et al., [@B38]       Adequate case definition; consecutive series of cases; hospital controls; adequate information concerning the selection and definition of controls; groups controlled for all the baseline characteristics except the LA[^\*^](#TN5){ref-type="table-fn"} diameter; ascertainment of outpatient exposure to adenosine text based on medical records for experiment groups; patients not blinded to case--control status.; same non-Response rate for both groups.                                                                                                                                                                                                                                                                                5
  Tebbenjohanns et al., [@B34]   Adequate case definition; consecutive series of cases; hospital controls; adequate information concerning the selection and definition of controls; groups controlled for all the baseline characteristics except the age and history with AF[^\*^](#TN5){ref-type="table-fn"},; ascertainment of outpatient exposure to adenosine text based on medical records for experiment groups; patients not blinded to case--control status.; same non-Response rate for both groups.                                                                                                                                                                                                                                                                   5

*Assessment of the quality of included studies according to Newcastle--Ottawa Scale for nonrandomized case--controls studies and the Cochrane Collaboration\'s tool for assessing risk of bias in randomized trials; ^\*^LA, left atrial; ^\*^AF, atrial fibrillation*.

###### 

Assessment of the quality of included studies in Group DC (+) and Group DC (−)[^\*^](#TN6){ref-type="table-fn"}.

  **Study**                 **Assessment**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                **Classification (attributable stars)**
  ------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------
  Zhang et al., [@B39]      Adequate case definition; consecutive series of cases; hospital controls; adequate information concerning the selection and definition of controls; groups controlled for all the baseline characteristics; ascertainment of outpatient exposure to adenosine text based on medical records for experiment groups and controls; patients not blinded to case--control status.; same non-Response rate for both groups.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        7
  Kim et al., [@B15]        Adequate case definition; consecutive series of cases; hospital controls; adequate information concerning the selection and definition of controls; groups controlled for all the baseline characteristics; ascertainment of outpatient exposure to adenosine text based on medical records for experiment groups and controls; patients not blinded to case--control status.; same non-Response rate for both groups.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        7
  Kaitani et al., [@B14]    Adequate case definition; consecutive series of cases; hospital controls; adequate information concerning the selection and definition of controls; groups controlled for all the baseline characteristics; ascertainment of outpatient exposure to adenosine text based on medical records for experiment groups and controls; patients not blinded to case--control status.; same non-Response rate for both groups.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        7
  Macle et al., [@B22]      Low risk of selection bias (randomization was done with permuted blocks of eight and the allocation sequence was computer-generated by an independent organization); low risk of performance bias (Patients were enrolled by study personnel and masked to their randomization assignment for the duration of the trial and study staff doing catheter ablations could not be masked to treatment allocation); low risk of detection bias (All efficacy and adverse outcomes were assessed by an independent adjudicating committee masked to treatment allocation); low risk of attrition bias (complete outcome for all the patients enrolled); low risk of reporting bias (we can find the research plan with "Adenosine following pulmonary vein isolation to target dormant conduction elimination (ADVICE): methods and rationale" though Pubmed); Unclear risk of other bias (insufficient information about other sources of bias).   --
  Matsuo et al., [@B23]     Adequate case definition; consecutive series of cases; hospital controls; adequate information concerning the selection and definition of controls; groups controlled for all the baseline characteristics; ascertainment of outpatient exposure to adenosine text based on medical records for experiment groups and controls; patients not blinded to case--control status.; same non-Response rate for both groups.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        7
  Miyazaki et al., [@B26]   Adequate case definition; consecutive series of cases; hospital controls; adequate information concerning the selection and definition of controls; groups controlled for all the baseline characteristics; ascertainment of outpatient exposure to adenosine text based on medical records for experiment groups and controls; patients not blinded to case--control status.; same non-Response rate for both groups.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        7
  Cheung et al., [@B2]      Adequate case definition; consecutive series of cases; hospital controls; adequate information concerning the selection and definition of controls; groups controlled for the baseline characteristics are not mentioned; ascertainment of outpatient exposure to adenosine text based on medical records for experiment groups and controls; patients not blinded to case--control status.; same non-Response rate for both groups.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          5
  Lin et al., [@B20]        Adequate case definition; consecutive series of cases; hospital controls; adequate information concerning the selection and definition of controls; groups controlled for all the baseline characteristics; ascertainment of outpatient exposure to adenosine text based on medical records for experiment groups and controls; patients not blinded to case--control status.; same non-Response rate for both groups.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        7

*DC, dormant conduction; ^\*^Assessment of the quality of included studies according to Newcastle--Ottawa Scale for nonrandomized case--controls studies and the Cochrane Collaboration\'s tool for assessing risk of bias in randomized trials*.

### Long-term Success Rate of PVI Between Group A (+) and Group A (−)

The pooled meta-analysis demonstrated that there was no significant difference in freedom from recurrent AF between Group A (+) and Group A (−) (RR = 1.08, 95% CI: 0.97--1.19, *P* = 0.16, I^2^ = 66%; Figure [2](#F2){ref-type="fig"}). A funnel plot plotting standard errors against the logarithms of the RR are shown in Figure [3](#F3){ref-type="fig"}, demonstrating no significant publication bias.

![Forest plot comparing long-term success rates of PVI between Group A (+) and Group A (−).](fphys-09-01861-g0002){#F2}

![Funnel plot of standard errors against logarithms of odds ratios for studies comparing long-term success rates of PVI between Group A (+) and Group A (−).](fphys-09-01861-g0003){#F3}

### Long-term Success Rate of PVI Between Group DC (+) and Group DC (−)

No significant difference was observed between Group DC (+) and Group DC (−) with a pooled RR of 1.01 (95% CI: 0. 91--1.12; *P* = 0. 88; I^2^ = 60%; Figure [4](#F4){ref-type="fig"}). A funnel plot plotting standard errors against the logarithms of the RR are shown in Figure [5](#F5){ref-type="fig"}, demonstrating no significant publication bias.

![Forest plot comparing long-term PVI success rate between Group DC (+) and Group DC (−).](fphys-09-01861-g0004){#F4}

![Funnel plot of standard errors against logarithms of odds ratios of studies comparing long-term PVI success rate between Group DC (+) and Group DC (−).](fphys-09-01861-g0005){#F5}

Subgroup Analyses
-----------------

Additional subgroup analyses were performed for radiofrequency catheter ablation (RFCA) and CB-2G catheter ablation for PVI in Group A (+) and Group A (−). For RFCA, no difference in success rate was observed in Group A (+) and Group A (−) for patients with a RR of 1.02 (95% CI: 0.89--1.17; *P* = 0.80; Figure [6](#F6){ref-type="fig"}), which was accompanied by significant heterogeneity (I^2^ = 73%). Similarly, for CB-2G, success rates for those who underwent adenosine testing (*n* = 134) were not significantly different from those who did not have such a test (*n* = 212), with a pooled RR of 1.18 (95% CI = 0. 99--1.42; *P* = 0.07; Figure [7](#F7){ref-type="fig"}) with significant heterogeneity (I^2^ = 62%).

![Subgroup analysis for CPVI.](fphys-09-01861-g0006){#F6}

![Subgroup analysis for CB-2G.](fphys-09-01861-g0007){#F7}

Sensitivity Analysis
--------------------

Sensitivity analysis included study design and adenosine test, and none of them showed significant interference with study outcomes. Results are shown in Table [4](#T7){ref-type="table"}.

###### 

Results of sensitivity analysis.

                                          **Studies**   **RR**   **95% CI**   ***p*-value[^\*^](#TN7){ref-type="table-fn"}**   **Study heterogeneity**            
  --------------------------------------- ------------- -------- ------------ ------------------------------------------------ ------------------------- --- ---- ----------------------------------------
  **GROUP A (+) AND GROUP A (−)**                                                                                                                                 
  RCT                                     3             0.92     0.75--1.14   0.46                                             10.10                     2   80   0.006[^\*^](#TN7){ref-type="table-fn"}
  AO[^\*^](#TN7){ref-type="table-fn"}     6             1.07     0.93--1.23   0.33                                             19.43                     5   74   0.002[^\*^](#TN7){ref-type="table-fn"}
  PSAF[^\*^](#TN7){ref-type="table-fn"}   4             1.01     0.82--1.24   0.95                                             15.05                     3   80   0.002[^\*^](#TN7){ref-type="table-fn"}
  **GROUP DC (+) AND GROUP DC (−)**                                                                                                                               
  AO[^\*^](#TN7){ref-type="table-fn"}     4             1.02     0.87--1.19   0.83                                             8.53                      3   65   0.04[^\*^](#TN7){ref-type="table-fn"}
  PSAF[^\*^](#TN7){ref-type="table-fn"}   3             0.98     0.90--1.08   0.70                                             2.61                      2   23   0.27

*Significance values; ^\*^AO, adenosine only; ^\*^PSAF, paroxysmal atrial fibrillation*.

Discussion {#s4}
==========

Adenosine testing after AF ablation procedures has been widely adopted for demonstrating DCs, which are further ablated to reduce AF recurrence rates (Hocini et al., [@B12]). However, in our study, the result of pooled meta-analysis suggested that adenosine test may not help to reduce the long-term AF recurrence after CPVI, and further subgroup analysis also confirmed the result. Some recent studies also suggested negative result of adenosine test based on CPVI (Theis et al., [@B36]; Ghanbari et al., [@B8]). The reason might be explained by the mechanism of PVI re-connection after CPVI ablation dose not totally attributed by DCs (Linz et al., [@B21]). Potential mechanisms of AF recurrence after CPVI may due to failure of trans-mural injury of PVAs (Rostock et al., [@B32]), heterogeneity of myocardial sleeves extending into the pulmonary veins (Ho et al., [@B11]) or so on. As a consequence, the necessity and applicability of adenosine test diminished in the context of CPVI adoption ablation strategy and Whether other techniques, such as pacing along the PVI line by the distal tip of the ablation catheter to identify viable myocardium or potential gaps (Schaeffer et al., [@B33]) improves PVI outcome should be investigated in the future.

However, a recent meta-analysis has shown that long-term success rates of PVI were improved by further eliminating DCs that have been identified by adenosine test for patients underwent segmental ablation for AF (McLellan et al., [@B25]). The discrepancy results with the results of the previous meta-analysis (McLellan et al., [@B25]) may due to improved ablation strategies (Ouyang et al., [@B30]). The 3-dimensional Electroanatomical Mapping System for RFA provides better visualization and reduce the need for excessive ablation (Ouyang et al., [@B30]). Ablation strategies based on CPVI ablation, instead of segmental ablation, were comprehensively adopted for AF patients either paroxysmal AF or persistent AF, leading to better AF control in the long-term (Gepstein et al., [@B7]). Previous studies had shown that segmental ablation was inferior to long term treatment compared with CPVI, and leads to more complications, such as pulmonary stenosis (Oral et al., [@B28]). Additionally, cryo-application offers spherical contact with the PV autrum (PVA), guided by annular Achieve catheter and vasography, provided CPVI by the single-shot technique (Nakagawa et al., [@B27]). Consequently, modifying skills and appliances, meaningful of adenosine administration may have diminished the need for AF re-ablation.

Complications arising from ablating DCs could further contribute to the lack of efficacy. For example, excessive ablation creates scarring of the atrial myocardium, which can serve as substrates for re-entry (Pappone et al., [@B31]; Tse et al., [@B37]). Indeed, a previous study compared anatomically guided CPVI with wide atrial ablation, demonstrating that the latter approach significantly increased the likelihood of micro-reentry ablation by producing areas of conduction slowing and block (Hocini et al., [@B12]). Moreover, we found that fluoroscopic time and procedure time were prolonged due to adenosine administration.

Limitations {#s5}
===========

This systematic review and meta-analysis has several potential limitations. There was moderate heterogeneity across the included studies, which may be due to the following factors. Firstly, differences in study participants between each study especially the types of AF, and in detection criteria were observed. Secondly, several studies have used additional methods during adenosine testing for provoking DCs, such as isoproterenol administration during adenosine test. Thirdly, the dose of adenosine, administration method and procedure (such as waiting period after adenosine) used to unmask dormant conduction was not uniform, this may affect the clinical outcomes. Fourthly, the successful rate of PVI may vary across medical centers due to variation in technical competencies, skills, and outcome measures. As such, the readers are advised to interpret the findings carefully. Nevertheless, funnel plot analysis revealed no significant publication bias. RCTs on CB-2G did not include a high number of participants and additional clinical trials are needed to confirm these findings.

Conclusions {#s6}
===========

In conclusion, regular adoption of adenosine test could not further improve PVI success rate basing on long-term observation and elimination of DCs provoked by adenosine after CPVI did not significantly reduce AF recurrence after catheter ablation.
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AF

:   atrial fibrillation

CPVI

:   circumferential pulmonary vein isolation

PVI

:   pulmonary vein isolation

DC

:   dormant conduction

PVs

:   pulmonary veins
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